Latest news with #Tarpeyo
Yahoo
08-05-2025
- Health
- Yahoo
Emerging Treatments Drive Notable Changes in IgA Nephropathy Care Across Key Global Markets, According to Spherix Global Insights
Products such as Tarpeyo (Calliditas), Filspari (Travere) and now Novartis' Fabhalta and Venrafia provide physicians more options than ever before. EXTON, PA, May 08, 2025 (GLOBE NEWSWIRE) -- With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA Nephropathy (IgAN) patients. Data from Spherix Global Insights' comprehensive Patient Chart Dynamix™ services—spanning over 2,300 patient charts across the US, EU5, Japan, and China—demonstrate the magnitude of this shift, highlighting differences in treatment patterns, product adoption, and future intent across markets. As standard treatment practice increasingly incorporates SGLT2 inhibitors—initially reserved for diabetes and then diabetic kidney disease—nephrologists are initiating these agents earlier in the treatment algorithm, citing emerging data supporting their protective effects in CKD, including IgAN. Adoption has grown substantially year-over-year in all surveyed markets. While regional differences exist, the early use of SGLT2 inhibitors, in combination with RAASi, is now widely accepted as foundational care for non-dialysis IgAN patients. Overlaying this supportive care are newly launched agents designed specifically for IgAN. Calliditas' Tarpeyo® (budesonide) and Travere's Filspari® (sparsentan) have quickly gained traction in the US, with prescribing steadily moving upstream in the treatment paradigm. Indeed, nearly one in five US IgAN patients are currently managed with Tarpeyo, and Filspari's use has nearly doubled in the past year alone. Across Europe, Kinpeygo—Tarpeyo's EU label—has seen notable growth, especially in Germany and the UK. Filspari's limited availability at the time of fielding across many regions somewhat constrained its uptake, though future use intentions are high as access expands. In China, Nefecon (budesonide) has rapidly secured a foothold, with many patients already initiated on therapy. Despite different access landscapes, nephrologists are aligned on one key goal: reducing proteinuria to below 0.5g/day. Yet, many patients remain above this threshold despite therapy, underscoring the need for additional, more effective options. Enter Novartis, with Fabhalta® (iptacopan), recently approved in the US and garnering early interest for use in later lines of therapy. Vanrafia®, also from Novartis, has just received its first approval and is poised to further expand the treatment armamentarium. Together, these products—alongside pipeline agents targeting the complement system, APRIL/BAFF pathways, and other novel MOAs—represent a new chapter in IgAN care focused on underlying disease pathophysiology. Importantly, Spherix's data highlight regional nuances in how nephrologists view and sequence these therapies. In Japan, tonsillectomy remains a widely accepted option and is often paired with systemic corticosteroids. In contrast, physicians in the US and China are increasingly moving away from broad immunosuppression in favor of targeted mechanisms with improved safety profiles. While there is general agreement on first-line strategies, subsequent lines of therapy are in flux, shaped by clinical experience, product availability, and evolving guideline recommendations. Physicians continue to prioritize clinical data demonstrating both proteinuria reduction and eGFR preservation when evaluating new options, though safety warnings remain a barrier to adoption for some. Even so, enthusiasm for therapies with novel mechanisms continues to grow, particularly in markets where patients remain difficult to manage despite standard therapies. With over five years of continuous tracking, Spherix Global Insights has established the most robust and consistent global dataset on IgAN, offering the industry's most comprehensive view of how real-world treatment decisions have evolved and how emerging therapies are being integrated into clinical practice. By continuing to track real-world patient management trends and comparing data across markets, Spherix delivers actionable insights that support strategic decision-making for stakeholders across the nephrology landscape. Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the 'why' behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: Spherix Global Insights Contacts Tucker Hurtado, Nephrology Franchise Head NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Tucker Hurtado, Nephrology Franchise Head Spherix Global Insights 4848794284 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
08-04-2025
- Health
- Associated Press
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
EXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the IgAN patient journey amid a rapidly evolving therapeutic landscape. As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating diagnosis, treatment decisions, and the daily realities of living with this chronic kidney condition. Fielded in early 2025 and developed in collaboration with the American Kidney Fund (AKF), the study reflects the voices of 127 patients diagnosed with IgAN. While many report satisfaction with newer branded therapies, substantial gaps persist in patient education, confidence, and affordability. The emotional burden of an IgAN diagnosis remains significant, with most respondents describing initial feelings of fear, confusion, or anxiety. A clear need emerged for better disease education – particularly around treatment expectations, progression, and financial resources. More than one-third of patients rely on support groups or charitable foundations for financial assistance, underscoring the role pharmaceutical companies can play in reducing barriers through accessible, patient-friendly resources. The research places special emphasis on patients currently treated with Tarpeyo, Filspari, and Fabhalta, all of which are associated with symptom relief and improved quality of life. However, challenges persist. Although many patients begin treatment feeling informed, issues related to cost, insurance coverage, and long-term affordability often complicate therapy initiation and adherence. These findings highlight opportunities for manufacturers to enhance onboarding and support through both provider-facing tools and direct-to-patient engagement strategies. The study also integrates insights from Spherix's latest Patient Chart Dynamix™: IgAN (US) study to provide complementary perspectives from nephrologists, offering a comprehensive view of how patient and physician perceptions align, and differ, when it comes to disease severity, treatment satisfaction, and care coordination. For commercial, medical, and access teams preparing to launch or expand within the IgAN space, Patient Dynamix™: IgAN (US) offers a critical resource for shaping brand strategy, refining support services, and ultimately improving patient outcomes. By leveraging these patient-level insights, pharmaceutical organizations can more effectively tailor messaging, reduce drop-off rates, and enhance their position as true partners in IgAN care. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of 1 in 7 Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and it has received 24 consecutive 4-Star ratings from Charity Navigator as well as the Platinum Seal of Transparency from Candid, formerly known as GuideStar. AKF Contacts NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.
